Physician profile
Bryan D Sofen
NPI 1043452139
$35,453.49
in general payments reported to CMS, 2019-2025
36 companies · $767 in 2025
The $767 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $14K · 2021: $3,435 · 2022: $750 · 2023: $880 · 2024: $1,277 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,749.08 |
| Education | $174.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19,160.43 | 2019-2024 | Otezla |
| Celgene Corporation | $10,191.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $644.29 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $499.52 | 2019-2025 | Ilumya |
| Biofrontera INC. | $471.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $462.86 | 2019-2025 | Libtayo, Dupixent |
| Abbvie INC. | $461.71 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $421.72 | 2021-2024 | Tremfya |
| Pfizer INC. | $397.98 | 2019-2023 | |
| Leo Pharma INC. | $238.48 | 2019-2023 | Adbry |
| Ucb, INC. | $222.30 | 2019-2025 | Bimzelx |
| Genentech USA, INC. | $221.23 | 2020-2024 | Erivedge |
| Lilly USA, LLC | $219.22 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $214.52 | 2019-2025 | |
| Galderma Laboratories, L.P. | $208.79 | 2019-2025 | Nemluvio |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.83 | 2022-2025 | Spevigo |
| Dermavant Sciences, INC. | $163.57 | 2023-2024 | Vtama |
| Almirall LLC | $157.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $151.79 | 2023-2025 | Sotyktu |
| Convatec INC. | $123.72 | 2024-2025 | |
| Revance Therapeutics, INC. | $121.22 | 2024 | Daxxify |
| Incyte Corporation | $97.57 | 2022-2025 | Opzelura |
| Kerecis Limited | $67.86 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.18 | 2019-2025 | Jublia |
| Organogenesis INC. | $48.99 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $47.25 | 2024-2025 | |
| Strata Skin Sciences, INC. | $34.89 | 2019-2025 | Xtrac |
| Dusa Pharmaceuticals, INC. | $31.33 | 2019 | |
| Organon LLC | $26.47 | 2025 | Vtama |
| Aclaris Therapeutics, INC. | $23.85 | 2019 | |
| Mimedx Group, INC. | $20.35 | 2024 | |
| Arcutis Biotherapeutics, INC. | $19.71 | 2023 | |
| Surgenex LLC | $18.94 | 2025 | Surmatrix, Renograft, Pellograft |
| Medline Industries LP | $17.87 | 2025 | |
| Allergan, INC. | $15.94 | 2022 | |
| Melinta Therapeutics, LLC | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Sofen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.